Hypoxia-mediated tumour targetingBINLEY, K; ASKHAM, Z; MARTIN, L et al.Gene therapy (Basingstoke). 2003, Vol 10, Num 7, pp 540-549, issn 0969-7128, 10 p.Article

Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMTTIETZE, Lutz F; SCHMUCK, Kianga.Current pharmaceutical design (Print). 2011, Vol 17, Num 32, pp 3527-3547, issn 1381-6128, 21 p.Article

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPTHELSBY, N. A; FERRY, D. M; PATTERSON, A. V et al.British journal of cancer. 2004, Vol 90, Num 5, pp 1084-1092, issn 0007-0920, 9 p.Article

Directed evolution for drug and nucleic acid deliveryHIDA, Kaoru; HANES, Justin; OSTERMEIER, Marc et al.Advanced drug delivery reviews. 2007, Vol 59, Num 15, pp 1562-1578, issn 0169-409X, 17 p.Article

The HIF-1-active microenvironment: An environmental target for cancer therapyKIZAKA-KONDOH, Shinae; TANAKA, Shotaro; HARADA, Hiroshi et al.Advanced drug delivery reviews. 2009, Vol 61, Num 7-8, pp 623-632, issn 0169-409X, 10 p.Article

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954PROSSER, G. A; COPP, J. N; SYDDALL, S. P et al.Biochemical pharmacology. 2010, Vol 79, Num 5, pp 678-687, issn 0006-2952, 10 p.Article

Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapyASCHE, Christian; DUMY, Pascal; CARREZ, Danièle et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 7, pp 1990-1994, issn 0960-894X, 5 p.Article

Recent Trends in Targeted Anticancer Prodrug and Conjugate DesignSINGH, Yashveer; PALOMBO, Matthew; SINKO, Patrick J et al.Current medicinal chemistry. 2008, Vol 15, Num 18, pp 1802-1826, issn 0929-8673, 25 p.Article

Prodrugs for improving tumor targetability and efficiencyMAHATO, Rubi; WANYI TAI; KUN CHENG et al.Advanced drug delivery reviews. 2011, Vol 63, Num 8, pp 659-670, issn 0169-409X, 12 p.Article

Viral vectors for gene-directed enzyme prodrug therapySCHEPELMANN, Silke; SPRINGER, Caroline J.Current gene therapy. 2006, Vol 6, Num 6, pp 647-670, issn 1566-5232, 24 p.Article

Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirusWANG, X. Y; MARTINIELLO-WILKS, R; WEBSTER, L. K et al.Gene therapy (Basingstoke). 2004, Vol 11, Num 21, pp 1559-1567, issn 0969-7128, 9 p.Article

Novel chimeric gene promoters responsive to hypoxia and ionizing radiationGRECO, O; MARPLES, B; DACHS, G. U et al.Gene therapy (Basingstoke). 2002, Vol 9, Num 20, pp 1403-1411, issn 0969-7128Article

Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefitLEE, K. C; HAMSTRA, D. A; BULLARAYASAMUDRAM, S et al.Gene therapy (Basingstoke). 2006, Vol 13, Num 2, pp 127-137, issn 0969-7128, 11 p.Article

Gene-directed enzyme prodrug therapy (GDEPT) : choice of prodrugsSPRINGER, C. J; NICULESCU-DUVAZ, I.Advanced drug delivery reviews. 1996, Vol 22, Num 3, pp 351-364, issn 0169-409XArticle

The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapiesDENNY, W. A; WILSON, W. R.Journal of pharmacy and pharmacology. 1998, Vol 50, Num 4, pp 387-394, issn 0022-3573Conference Paper

Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapyHAY, Michael P; WILSON, William R; DENNY, William A et al.Bioorganic & medicinal chemistry. 2005, Vol 13, Num 12, pp 4043-4055, issn 0968-0896, 13 p.Article

Cytochrome P450-Activated Prodrugs : Targeted Drug DeliveryHUTTUNEN, Kristiina M; MÄHÖNEN, Niina; RAUNIO, Hannu et al.Current medicinal chemistry. 2008, Vol 15, Num 23, pp 2346-2365, issn 0929-8673, 20 p.Article

Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugsLONGQIN HU; XINGHUA WU; KNOX, Richard J et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 13, pp 3986-3991, issn 0960-894X, 6 p.Article

Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systemsNICULESCU-DUVAZ, I; SCANLON, I; NICULESCU-DUVAZ, D et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 10, pp 2651-2658, issn 0022-2623, 8 p.Article

Cancer gene therapy: Part 2. Candidate transgenes and their clinical developmentHARRINGTON, Kevin J; MELCHER, Alan A; BATEMAN, Andrew R et al.Clinical oncology (Springer. Print). 2002, Vol 14, Num 2, pp 148-169, issn 0936-6555, 22 p.Article

Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cellsSIMONOVA, Maria; WALL, Alexander; WEISSLEDER, Ralph et al.Cancer research (Baltimore). 2000, Vol 60, Num 23, pp 6656-6662, issn 0008-5472Article

Optimizing radiation-responsive gene promoters for radiogenetic cancer therapySCOTT, S. D; JOINER, M. C; MARPLES, B et al.Gene therapy (Basingstoke). 2002, Vol 9, Num 20, pp 1396-1402, issn 0969-7128Article

Advanced drug delivery reviews : enzyme prodrug therapySHERWOOD, R. F.Advanced drug delivery reviews. 1996, Vol 22, Num 3, pp 269-288, issn 0169-409XArticle

Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductaseBILSLAND, Alan E; ANDERSON, Claire J; FLETCHER-MONAGHAN, Aileen J et al.Oncogene (Basingstoke). 2003, Vol 22, Num 3, pp 370-380, issn 0950-9232, 11 p.Article

Metallocarboxypeptidases : Emerging drug targets in biomedicine : Recent advances and future prospect in protease targetingAROLAS, Joan L; VENDRELL, Josep; AVILES, Francesc X et al.Current pharmaceutical design. 2007, Vol 13, Num 4, pp 349-366, issn 1381-6128, 18 p.Article